Statements (46)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
monoclonal antibody
|
| gptkbp:activeDuring |
gptkb:ocrelizumab
|
| gptkbp:administrativeDivision |
every 6 months
|
| gptkbp:approves |
gptkb:FDA
|
| gptkbp:availability |
prescription only
|
| gptkbp:brand |
gptkb:Ocrelizumab
|
| gptkbp:clinicalTrials |
Phase III
relapsing forms of multiple sclerosis primary progressive multiple sclerosis OPERA I OPERA II ORATORIO |
| gptkbp:contraindication |
active infections
neutropenia liver problems malignancies active hepatitis B infection |
| gptkbp:dosageForm |
solution for infusion
|
| gptkbp:drugInterdiction |
immunomodulator
live vaccines other immunosuppressants half-life of approximately 26 days |
| gptkbp:formulation |
lyophilized powder
|
| gptkbp:hasPopulation |
adults
|
| gptkbp:healthcare |
important for efficacy
|
| https://www.w3.org/2000/01/rdf-schema#label |
Ocrevus
|
| gptkbp:impact |
ongoing therapy
|
| gptkbp:is_monitored_by |
liver function tests
complete blood count |
| gptkbp:lastProduced |
2017
|
| gptkbp:launchSite |
vein
|
| gptkbp:manufacturer |
gptkb:Genentech
|
| gptkbp:marketedAs |
gptkb:European_Union
gptkb:United_States |
| gptkbp:offers |
high
|
| gptkbp:patentExpiration |
2028
|
| gptkbp:postRetirementCareer |
100 mL
|
| gptkbp:route |
intravenous
|
| gptkbp:safetyFeatures |
risk of progressive multifocal leukoencephalopathy (PML)
|
| gptkbp:sideEffect |
infections
infusion reactions hypersensitivity reactions |
| gptkbp:storage |
refrigerated
|
| gptkbp:triggerType |
CD20 B-cell depletion
|
| gptkbp:type |
gptkb:ocrelizumab
|
| gptkbp:usedFor |
treatment of multiple sclerosis
|